Literature DB >> 24708934

Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis.

M Kennedy1, A Papneja, A Thavaneswaran, V Chandran, D D Gladman.   

Abstract

OBJECTIVES: Psoriatic arthritis (PsA) is a unique inflammatory musculoskeletal disorder associated with psoriasis. Although high rates of absenteeism have been associated with PsA, less is known about the impact of the disease on the productivity of patients who remain at work. The aim of this study was to identify factors associated with reduced work productivity, as measured by the Work Limitations Questionnaire (WLQ), among patients with PsA.
METHODS: Patients attending a single Psoriatic Arthritis Clinic were recruited for participation. Employed participants (including homemakers) first completed a Questionnaire for the Assessment of Work-Related Factors (QAWRF). Eligible participants then completed the WLQ. WLQ scores were used as the dependent variable in linear and logistic regression analyses. Independent variables assessed in this study include work characteristics, demographic factors, and clinical measures.
RESULTS: One hundred and eighty-six eligible patients (60.9% males) returned their assessment forms for analysis. The mean reduction in work productivity due to illness was 4.3%. In univariate linear regression analysis, work productivity was significantly associated with sex, education status, Psoriasis Area and Severity Index (PASI), AJC, ESR, Functional Co-morbidity Index (FCI), and support at work; associations with gender, ESR, FCI, and medications were also significant in a reduced multivariate model.
CONCLUSIONS: Work productivity was associated with demographic, clinical, and work-related factors in PsA. These variables may be useful in identifying patients who require more aggressive intervention, including the use of effective drugs to control disease activity and advocacy for a more supportive work environment.

Entities:  

Mesh:

Year:  2014        PMID: 24708934

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting.

Authors:  Neal Bhatia; Andrew Blauvelt; Marc Brown; Whitney High; Craig T Leonardi; Ted Rosen; Linda Stein Gold; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

2.  Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study.

Authors:  Rieke Alten; P G Conaghan; V Strand; E Sullivan; S Blackburn; H Tian; K Gandhi; S M Jugl; A Deodhar
Journal:  Clin Rheumatol       Date:  2019-02-04       Impact factor: 2.980

3.  Construct Validity and Scoring Methods of the World Health Organization: Health and Work Performance Questionnaire Among Workers With Arthritis and Rheumatological Conditions.

Authors:  Rawan AlHeresh; Michael P LaValley; Wendy Coster; Julie J Keysor
Journal:  J Occup Environ Med       Date:  2017-06       Impact factor: 2.162

4.  The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.

Authors:  Ashok Jha; Alex Upton; William C N Dunlop; Ron Akehurst
Journal:  Adv Ther       Date:  2015-09-05       Impact factor: 3.845

Review 5.  The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review.

Authors:  Juan D Cañete; Jose Antonio Pinto Tasende; Francisco José Rebollo Laserna; Susana Gómez Castro; Rubén Queiro
Journal:  Rheumatol Ther       Date:  2020-04-08

6.  The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.

Authors:  Alexis Ogdie; Jessica A Walsh; Soumya D Chakravarty; Steven Peterson; Kim Hung Lo; Lilianne Kim; Nan Li; Elizabeth C Hsia; Eric K H Chan; Arthur Kavanaugh; M Elaine Husni
Journal:  Clin Rheumatol       Date:  2021-03-02       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.